Voyager Therapeutics (NASDAQ:VYGR) had its price target reduced by analysts at Robert W. Baird from $31.00 to $27.00 in a research report issued to clients and investors on Thursday. The brokerage currently has an “outperform” rating on the stock. Robert W. Baird’s price objective indicates a potential upside of 119.16% from the stock’s previous close.
A number of other equities analysts have also recently weighed in on the company. HC Wainwright set a $30.00 price target on Voyager Therapeutics and gave the stock a “buy” rating in a report on Tuesday, July 17th. Canaccord Genuity restated a “buy” rating and issued a $31.00 price target on shares of Voyager Therapeutics in a report on Tuesday, July 17th. Zacks Investment Research upgraded Voyager Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 11th. BidaskClub upgraded Voyager Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, August 25th. Finally, BTIG Research restated a “buy” rating and issued a $32.00 price target on shares of Voyager Therapeutics in a report on Monday, September 10th. Four analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Voyager Therapeutics has an average rating of “Buy” and an average target price of $28.00.
Shares of NASDAQ:VYGR opened at $12.32 on Thursday. Voyager Therapeutics has a 1 year low of $11.00 and a 1 year high of $31.91.
In other Voyager Therapeutics news, Director James A. Geraghty bought 3,000 shares of Voyager Therapeutics stock in a transaction dated Monday, September 10th. The stock was bought at an average cost of $19.39 per share, for a total transaction of $58,170.00. Following the purchase, the director now owns 76,588 shares in the company, valued at approximately $1,485,041.32. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Glenn Pierce bought 5,000 shares of Voyager Therapeutics stock in a transaction dated Wednesday, September 12th. The shares were acquired at an average price of $18.44 per share, with a total value of $92,200.00. The disclosure for this purchase can be found here. In the last 90 days, insiders acquired 11,000 shares of company stock valued at $205,300. 33.60% of the stock is owned by company insiders.
Several institutional investors have recently added to or reduced their stakes in the company. BB Biotech AG boosted its stake in shares of Voyager Therapeutics by 11.5% during the 3rd quarter. BB Biotech AG now owns 2,822,641 shares of the company’s stock valued at $53,404,000 after buying an additional 290,000 shares during the last quarter. BlackRock Inc. boosted its stake in shares of Voyager Therapeutics by 1.0% during the 3rd quarter. BlackRock Inc. now owns 1,863,766 shares of the company’s stock valued at $35,262,000 after buying an additional 18,060 shares during the last quarter. Wells Fargo & Company MN boosted its stake in shares of Voyager Therapeutics by 18.6% during the 3rd quarter. Wells Fargo & Company MN now owns 534,087 shares of the company’s stock valued at $10,105,000 after buying an additional 83,607 shares during the last quarter. Laurion Capital Management LP boosted its stake in shares of Voyager Therapeutics by 23.2% during the 2nd quarter. Laurion Capital Management LP now owns 355,950 shares of the company’s stock valued at $6,955,000 after buying an additional 66,987 shares during the last quarter. Finally, Northern Trust Corp boosted its stake in shares of Voyager Therapeutics by 33.5% during the 2nd quarter. Northern Trust Corp now owns 267,441 shares of the company’s stock valued at $5,226,000 after buying an additional 67,063 shares during the last quarter. Institutional investors own 85.09% of the company’s stock.
Voyager Therapeutics Company Profile
Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trials for the treatment of advanced Parkinson's disease.
Featured Article: The Role of a Fiduciary and Individual Investors
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.